L. Gage Biography and Net Worth

L. Patrick Gage, Ph.D. has served as a member of our Board of Directors since November 2009 and as Chairman of the Board of Directors since March 2010. Since July 2002, Dr. Gage has served as a consultant to the biopharmaceutical industry, including serving as an advisor to venture capital firms. From 1998 to 2002, Dr. Gage was President of Wyeth Research and subsequently also Senior Vice President, Science and Technology. From 1989 to 1998, he held roles of increasing responsibility at Genetics Institute, Inc., first as head of Research and Development, then as Chief Operating Officer, and eventually as President. From 1971 to 1989, Dr. Gage held various positions in research management with Hoffmann-La Roche Inc., most recently serving as Vice President responsible for U.S. drug discovery. Dr. Gage has served as the Chairman of the Board of Directors of Tetraphase Pharmaceuticals since April 2013. Dr. Gage served on the Board of Directors of Neose Technologies from 2002 to 2009, and as the Chairman of its Board of Directors from 2006 to 2009. He served on PDL BioPharma, Inc.’s Board of Directors from 2003 to 2008, as the Chairman of its Board of Directors in 2007, and as its Interim Chief Executive Officer from 2007 to 2008. Dr. Gage earned a bachelor’s degree in Physics from the Massachusetts Institute of Technology and a Ph.D. in Biophysics from the University of Chicago.

What is L. Patrick Gage's net worth?: The estimated net worth of L. Patrick Gage is at least $2.10 million as of March 19th, 2021. Mr. Gage owns 31,762 shares of Cytokinetics stock worth more than $2,102,327 as of April 24th. This net worth estimate does not reflect any other assets that Mr. Gage may own. Learn More about L. Patrick Gage's net worth.
How do I contact L. Patrick Gage?: The corporate mailing address for Mr. Gage and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on L. Patrick Gage's contact information.
Has L. Patrick Gage been buying or selling shares of Cytokinetics?: L. Patrick Gage has not been actively trading shares of Cytokinetics over the course of the past ninety days. Most recently, L Patrick Gage sold 26,468 shares of the business's stock in a transaction on Monday, November 8th. The shares were sold at an average price of $41.33, for a transaction totalling $1,093,922.44. Learn More on L. Patrick Gage's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (CEO), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 34 times. They sold a total of 379,465 shares worth more than $20,438,114.45. The most recent insider tranaction occured on April, 9th when EVP Fady Ibraham Malik sold 32,605 shares worth more than $2,422,877.55. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 4/9/2024.

L. Patrick Gage Insider Trading History at Cytokinetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/8/2021	Sell	26,468	$41.33	$1,093,922.44
3/19/2021	Sell	10,000	$24.45	$244,500.00	31,762
3/12/2021	Sell	10,339	$21.22	$219,393.58	28,768
12/15/2020	Sell	7,716	$21.00	$162,036.00	28,520
8/31/2015	Buy	1,000	$6.95	$6,950.00	30,000
8/20/2015	Buy	10,000	$6.55	$65,500.00	30,000
5/6/2015	Buy	10,000	$5.71	$57,100.00
5/9/2014	Buy	10,850	$4.09	$44,376.50	10,000

L. Patrick Gage Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $66.82

$65.68

$67.45

50 Day Range

MA: $70.61

$63.75

$80.99

2 Week Range

Now: $66.82

$25.98

$110.25

Volume

807,437 shs

Average Volume

2,949,583 shs

Market Capitalization

$6.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…